Millions of disabled people and seniors worldwide suffering from impaired walking, are confined to a sedentary lifestyle in a wheelchair, causing health deterioration, poor quality of life, and high medical expenses – a burden for the disabled, their families and health insurers. Numerous studies have demonstrated the physical and mental health benefits of wheelchairs with a standing position, which enables users to mobilize body parts, and reduce falls when reaching for high objects.
As the number of wheelchair and scooter users grows, due to both increasing accidents and aging populations, many seek a smart mobility device that will provide fully-functional standing and sitting mobility, improve health, enhance social inclusion, and reduce healthcare and living expenses.
UPnRIDE is a wheeled robotic device, providing upright and seated mobility both for wheelchair users, and for anyone who is unable to, or has difficulty standing or walking.
UPnRIDE offers numerous medical, psychological, and economic benefits, ensuring safety while standing, sitting, and shifting between positions, in practically any urban Environment.
Product Information is available from UPnRIDE Website.
Engineers from MIT and Singapore University of Technology and Design (SUTD) are using light to print three-dimensional structures that “remember” their original shapes. Even after being stretched, twisted, and bent at extreme angles, the structures — from small coils and multimaterial flowers, to an inch-tall replica of the Eiffel tower — sprang back to their original forms within seconds of being heated to a certain temperature “sweet spot.”
For some structures, the researchers were able to print micron-scale features as small as the diameter of a human hair — dimensions that are at least one-tenth as big as what others have been able to achieve with printable shape-memory materials.
Full story is available from MIT website.
Multidrug resistance (MDR) is the mechanism by which many cancers develop resistance to chemotherapy drugs, resulting in minimal cell death and the expansion of drug-resistant tumors. To address the problem of resistance, researchers have developed nanoparticles that simultaneously deliver chemotherapy drugs to tumors and inhibit the MDR proteins that pump the therapeutic drugs out of the cell. The process is known as chemosensitization, as blocking this resistance renders the tumor highly sensitive to the cancer-killing chemotherapy.
The two publications report on the engineering of two separate nanoparticles that test different strategies for achieving chemosensitization of cancer cells. The first targets MDR breast cancer. The engineered round nanoparticle is made of several layers. The center of the particle is loaded with the anti-cancer drug doxorubicin. The drug is surrounded by a water-repelling (hydrophobic) capsule to protect it from the watery environment when the particle is injected into the circulatory system of an experimental animal or individual with cancer.
The particle has several outer layers with different properties. One of the outermost components, a molecule called PEG, is hydrophilic (mixes with water) and helps the particle move through the bloodstream until it encounters the breast tumor cells. Another component on the surface of the particle, biotin, functions to bind specifically to the cancer cells and helps the drug-carrying nanoparticle to enter the cell.
Once inside the breast cancer cell, a fourth component called curcumin, which is intertwined with the doxorubicin center, is released along with the doxorubicin. The curcumin is the component that blocks the cell machinery that would pump the doxorubicin out of the cell. Without the ability to pump out the medicine, the cell is exposed to very high concentration of doxorubicin, which kills the breast cancer cells.
Full story can be found from NIH website.
An experimental cancer drug works differently than intended and shows significant promise for stopping melanoma and possibly other forms of cancer, research from the UVA School of Medicine suggests. The findings also indicate the drug may be effective against melanomas that have resisted other forms of treatment.
The drug, pevonedistat, is already being tested in people. Scientists have been uncertain exactly how it kills cancer cells, as it shuts down many different cellular proteins – hundreds if not thousands. But the UVA researchers, led by Tarek Abbas, PhD, of the Department of Radiation Oncology and the UVA Cancer Center, have determined that the drug acts upon a particular protein that melanomas and other cancers rely on to replicate with great speed and deadly effect. By denying the cancers this essential ingredient, doctors may be able to stop melanomas and other forms of the disease.
For more information please visit University of Virginia website.
ResMed welcomed positive results from the independent Home Oxygen Therapy- Home Mechanical Ventilation (HOT-HMV) study[i] regarding the benefits of home non-invasive ventilation (NIV). Portable oxygen therapy, remote monitoring technology and home NIV are key components of ResMed’s COPD management offering.
The HOT-HMV study shows that the addition of home NIV to home oxygen therapy improves admission-free survival in hypercapnic COPD patients (those with high levels of carbon dioxide in the blood) following a life-threatening exacerbation of COPD requiring acute NIV.1 This includes an increase in patients’ median (hospital) admission-free survival from 1.4 months in the group receiving HOT only, to 4.3 months in the group receiving HOT plus home NIV, with an adjusted hazard ratio of 0.49 (0.31-0.77); p=0.002.
ResMed home NIV solutions are also connected to AirView™, ResMed’s cloud-based patient management system, which ensures healthcare professionals can remotely identify patients in need of attention, make informed treatment decisions and deliver timely interventions. In addition to helping physicians better manage COPD patients on home NIV, AirView also enables home care providers to optimise business efficiencies and allows them to focus existing resources on high-value activities. Resmed’s cloud-connected ventilators provide peace of mind to patients and their families and help improve their overall experience living with COPD.
A press release can be found from ResMed website.
BD announced general availability of the latest software release of Pyxis™ ES System, delivering patient safety and workflow benefits for health systems’ medication management.
Key innovations and enhancements in the new software version include:
- Advanced server scalability and optimization to meet the needs of growing health systems with flexible deployment options and centralized database management features.
- Expanded return and waste processes to support patient safety and clinical efficiency with workflow, documentation and interface enhancements.
- Support for advanced half-height CUBIE™ drawers and pockets, bringing enhanced security and reliability to the flexible storage space and configurability options for which CUBIE technology is known.
- New Medication Label Module that can print a patient-specific medication label upon removal to support patient safety and compliance with Joint Commission requirements. Proper medication labeling can help reduce medication errors, missing doses, and waste caused by mislabeled, open multi-use medications.
- Enhanced server functionality to provide more flexibility through medication configuration and user permissions, plus improved reporting features. These features support system and data security as well as medication safety and standardization.
The Pyxis ES platform promotes a patient-centric healthcare model, leveraging healthcare information technology systems and Active Directory integration to enable a single health system formulary, simplified identity management and workflow enhancements. The platform enables pharmacists to manage medications remotely and eliminate redundant tasks. Nurses can readily access secured medications using safe, simple workflows centered on the patient.
A press release can be found here.